Arachidonic acid is metabolized by means of P450 isoenzyme(s) to form epoxyeicosatrienoic acids (EETs) and their corresponding dihydroxy derivatives (DHETs). In the present study, we established the presence in human urine of 8,9-, 11,12-, and 14,15-EETs and their corresponding DHETs by developing quantitative assays and using negative ion, chemical ionization GC/MS and octadeuterated internal standards. Urinary excretion of 8,9-and 11,12-DHET increased in healthy pregnant women compared with nonpregnant female volunteers. By contrast, excretion of 11,12-DHET and 14,15-DHET, but not the 8,9-DHET regioisomer, increased even further in patients with pregnancy-induced hypertension. Intravenous administration of [3H]14,15-EET to three dogs markedly increased its DHET in plasma. The terminal half-life ranged from 7.9-12.3 min and the volume of distribution (3.5-5.3 liters) suggested limited distribution outside the plasma compartment. Negligible radioactivity was detected in urine; this fact infers that under physiological circumstances, urinary DHETs largely derive from the kidney. That P450 metabolites of arachidonic acid are formed in humans supports the hypothesis that these metabolites contribute to the physiological response to normal pregnancy and the pathophysiology of pregnancy-induced hypertension.
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Studies in vitro have demonstrated that arachidonic acid is metabolized by P450 monooxygenases (1) (2) (3) . Indeed, a P450 isoenzyme with substrate specificity for arachidonate acid has recently been purified from human liver (4) . The products of this reaction include hydroxyeicosatetraenoic acids, to and w-1 alcohols, and epoxyeicosatrienoic acids (EETs) and their corresponding diols (5) .
Among the biological properties of cytochrome P450-dependent arachidonic acid metabolites in vitro are the modulation of vascular tone (6) (7) (8) and the regulation of ion transport (9, 10) and water handling (11) in the renal tubule and toad bladder (12) . These metabolites inhibit Na+/K+-transporting ATPase in the cornea (13) , depress glomerular filtration (14) and inhibit platelet function (15) . In addition, the vascular capacity to form these compounds has recently been shown (16, 17) to be exaggerated in several animal models of hypertension.
Despite these observations and the regionally selective formation of endogenous EETs in rat liver (18) , skepticism has persisted about the role of EETs in human disease in vivo. This uncertainty stems from a paucity of information on the actual synthesis of these compounds in vivo (19) and caution in extrapolating tissue capacity for forming EETs in the in vivo situation. For example, for other arachidonic acid metabolites, tissue capacity exceeds in vivo formation rates by orders of magnitude and has been a misleading guide to alterations in prostaglandin biosynthesis (20) .
To study whether disordered EET formation might contribute to the pathophysiology of human disease, we assessed the in vivo synthesis of EETs in a setting where their properties might be of pathophysiological relevance, that of pregnancy-induced hypertension (PIH) (21) (22) (23) (24) in a 1.0-ml reaction vial and concentrated to dryness under a nitrogen stream. The arachidonic acid was then dissolved in 31 ,ul of dry methylene chloride and the vial was cooled at 0°C in an ice-water slurry. m-Chloroperoxybenzoic acid was then added in 69,u of dry methylene chloride and the solution was placed under dry argon, mixed on a Vortex mixer and warmed to room temperature for >1 hr. The solvent was next removed with a stream of dry nitrogen, and the reactants were redissolved in methanol/water/acetic acid 80:20:0.01 (vol/vol/vol). The products were chromatographed over a 5-gm reversed-phase column (4.6 x 250 mm; Altex) using methanol/water/acetic acid, 80:20:0.01 (vol/vol/vol) as the mobile phase at a flow rate of 1.0 ml per min. Absorbance was monitored at 210 nm and the epoxides were manually collected. The 14,15-epoxide appeared at 16.1 min as a single peak. The 11,12-epoxide appeared at 18.4 min and was collected as a mixture with the 8,9-epoxide, which appeared at 19.1 min. The 14,15-epoxide was used without further purification, whereas the 11,12-epoxide was separated from the 8,9-epoxide by straight-phase chromatography. Thus, the 8,9-and 11,12-epoxides were concentrated to dryness and taken up in 100 ,lI of hexane. They were then chromatographed over a straight-phase chromatography column (5 ,um reversed-phase 4.6 x 250 mm; Altex) using hexane/isopropanol/acetic acid, 100:0.4:0.1 (vol/vol/vol) as the mobile phase at a flow rate of 2.0 ml/min. Absorbance was monitored at 210 nm and the epoxides were again manually collected. The 11,12-epoxide appeared at 17.2 min and the 8.9-epoxide appeared at 22.9 min. The epoxides were then used without further purification after quantitation by comparison with a known amount of undeuterated synthetic material.
Extraction and purification. The approach taken was similar to that used by Turk et al. (25) . Ten microliters of methanol were added to 10 ml of urine containing a mixture of the octadeuterated analogs of the 8,9-, 11,12-, and 14,15-EETs. After equilibrating for -'15 min at room temperature, 1 ml of 70% (vol/vol) perchloric acid was added and the samples were allowed to stand at room temperature for 6 hr. Acidification quantitatively converted the epoxides to their respective diols. The urine was passed through a C18 cartridge (PrepSep, Fisher) conditioned with 2 ml of methanol Abbreviations: EET, epoxyeicosatrienoic acid; DHET, dihydroxy derivative of EET; PIH, pregnancy-induced hypertension.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. and 2 ml of water. The cartridge was then washed with 10 ml of 60% (vol/vol) methanol/water and dried by applying a vacuum. Diols were eluted with 1 10 pg/ml. Study population. The patients' clinical parameters are displayed in Table 1 . All patients had hypertension and proteinuria and the majority had low platelet counts. Control groups consisted of normotensive pregnant women and of age-matched female volunteers who had a negative pregnancy test.
Assessment of the origin of urinary EETs. Because of a recent report (26) identifying a product of human reproductive tissues that comigrates with authentic 14,15-EET, we selected this isomer as the focus of studies designed to assess the potential extrarenal contribution to urinary DHETs.
[3H]14,15-EET was synthesized by the same procedure used for the deuterated analog. Thirty microcuries (1 Ci = 37 GBq) was mixed with 1.5 mg of unlabeled material to give a specific activity of 6.4 uCi/4mol. The sodium salt was attained by dissolving equivalent nmol of 14,15-EET in 50 mM Na2CO3. This mixture was then diluted to 10 ml with saline and injected as a bolus into the antecubital vein of two mongreldogs anesthetized with pentobarbitone 20 mg/kg i.v. supplemented with 1-2 mg/kg as required. A third anesthetized dog was given only the unlabeled material.
Ten-milliliter blood samples were collected from the contralateral vein before injection, and 0.5, 1, 2, 5, 15, and 30 min and 1, 2, 4, and 8 hr afterward into syringes containing EDTA and (3-hydroxytoluene at 5 mM and 0.002% final concentrations, respectively. Urine was collected through a bladder catheter 1 hr before injection and at 1-hr intervals for 8 hr in the two dogs that received radioactive material. Plasma and urine samples were immediately treated and stored frozen until assayed.
Statistical and pharmacokinetic analysis. Comparison between the groups was based on nonparametric analysis of variance followed by pairwise comparisons as appropriate (27) . Pharmacokinetic analysis was based on the plasma concentrations of 14,15-DHET (as measured by GC/MS)-which fell below the limit of detection of the method 1 hr after injection-and were fitted to a two-compartment model (28) . Systemic clearance was calculated as the ratio of the dose of [3H114,15-EET infused to the area under the plasma concentration time curve with values >1 hr extrapolated to infinity. Areas under the plasma concentration time curves were calculated by using the logarithmic trapezoidal rule for descending data (29) .
RESULTS
Definitive confirmation of the presence of EETs in human urine was based on a synthetic compound characterized by electron impact mass spectra of the methyl ester bistrimethylsilyl ether derivatives of the diols. A representative spectrum of the 14,15-diol is depicted in Fig 1. Urinary excretion of 14,15-DHET (Fig. 2 Top) in nonpregnant women ranged from below limits ofdetection (==3 pg/mg of creatinine) to 24 pg/mg of creatinine. In healthy pregnant women, there was a trend toward an increase in 14,15-DHET (range, <10-118) with a median of 85 pg/mg of creatinine; however, the difference was not statistically significant. Urinary excretion in patients with severe PIH ranged between 679 and 22,000 pg/mg of creatinine (median, 2781) and was significantly elevated (P < 0.05) compared with the levels excreted in healthy pregnant women. Similarly, urinary excretion of 11,12-DHET (Fig. 2 Middle) was increased in healthy pregnancy as compared with nonpregnant women (range, 23-142.3 versus <3-17 pg/mg of creatinine; median, 43 versus 3; P < 0.01) and a further marked increase (range, 104-5500 pg/mg of creatinine; median, 364; P < 0.01) was seen in patients with pregnancyinduced hypertension. By contrast, urinary excretion of the 8,9-isomer (Fig. 2 Bottom) was increased in normal pregnancy (range, 58.9-394 versus 5.1-110 pg/mg of creatinine; median, 121 versus 27.1 pg/mg of creatinine; P < 0.001) with no further increase in women affected with severe pregnancyinduced hypertension (range, 85-643; median, 200; P = not significant).
After the bolus injection of [3H]14,15-EET, the concentration of 14,15-DHET (as detected by GC/MS) in dog plasma went up from a baseline of 0.33 + 0.6 ng/ml to 781 + 82.5 ng/ml after 30 sec. When a two-compartment pharmacokinetic analysis was used, 14,15-DHET disappeared from the circulation with a median terminal half-life of 11.9 min (Table 2; Fig. 3) . However, only a negligible percentage of the radioactivity injected appeared in the urine of the two dogs in which it was measured during the 8 hr after injection ( Table  3 ). The low (median 4.8 liters) volume of distribution was consistent with the compound being largely confined to the plasma compartment ( In the present study, we provide evidence for endogenous formation of P450-derived metabolites of arachidonic acid in humans. Consistent with this finding reflecting formation of the compounds in vivo, rather than autoxidation of arachidonic acid in urine ex vivo, was the observation that quantitation was not influenced by adding the antioxidant triphenylphosphine to urine or by delaying analysis of the sample at room temperature for 24 hr.
To address the hypothesis that EETs might be important in human disease, we have searched for alterations in their biosynthesis in a setting where their biological properties might be relevant. Pregnancy-induced hypertension is a common complication of pregnancy and is associated with both fetal and maternal morbidity (22, 31, 32) . Although the cause of this disease is unknown, it is characterized by elevated blood pressure, decreased plasma volume, and decreased placental blood flow. Renal abnormalities include decreased glomerular filtration rate and renal plasma flow (23) .
Abnormalities of eicosanoid formation have been described in PIH. For example, the increase in prostacyclin biosynthesis, which characterizes normal pregnancy, is blunted in women destined to develop PIH (33) . This may relate to the increase in vascular sensitivity to infused pressor agents (34, 35) , which also precedes the rise in blood pressure in such patients (36) . Platelets are activated in normal pregnancy (37) and this fact is reflected by an increase in the biosynthesis of the predominant cyclooxygenase product in platelets, thromboxane A2 (38) . We have recently observed a further increment in thromboxane formation in patients with moderate-to-severe PIH. This condition correlates with their mean arterial pressure, plasma lactate dehydrogenase, and the degree of thrombocytopenia (39) . Several small studies, which suggest that pretreatment with aspirin may reduce the incidence of PIH in women at risk of developing the disease (40) (41) (42) (43) , also support the possibility that thromboxane formation is of functional importance, perhaps contributing to reduced placental blood flow (22, 24) .
In the present study, we provide evidence that biosynthesis of the P450-derived metabolites of arachidonic acid is altered in healthy pregnant women compared with nonpregnant controls. Patients with established PIH had alterations in EET biosynthesis distinct from and additional to those seen in normal pregnancy. This result is most unlikely to reflect either nonspecific autoxidation of an increase in urinary arachidonic acid or a generalized induction of cytochrome P450 in pregnancy. In both cases, excretion of all four isomers would be increased to a similar extent. By contrast, we found that while biosynthesis of the 11,12-and 8,9-DHETs was increased in healthy pregnant women, excretion (27) . See text for details. developed for a P450 with high affinity for arachidonic acid expressed in the lungs of pregnant rabbits (45) .
Should P450-derived metabolites of arachidonic acid have a role in pregnancy and/or its hypertensive complication, one possible site of action is the kidney. Studies in vitro (46, 47) have shown that these compounds are major products of PIH arachidonic acid metabolism in the renal cortex and the cells of the thick ascending limb of the loop of Henle and are endogenous constituents of renal tissue (48) . In rat kidney, EETs constitute =1 ng/g of wet tissue (14) . Schwartzmann et al. (49) have partially identified the major arachidonic acid products of the cells of the thick ascending limb of Henle's loop as 11,12-DHET and 5,6-EET. The chromatographic fractions corresponding to these products were shown to inhibit Na+/K+-ATPase and to relax vascular smooth muscle, respectively. (R)-12-Hydroxyeicosatetraenoic acid, a * possible derivative of 11,12-DHET, inhibits Na+/K+-* ATPase in the cornea (10) . The tissue of origin of the compounds we measured in human urine was not addressed in this study. Given the tentative identification of 14,15-EET as a product of human reproductive tissues (26) and that the increment in 14,15-DHET excretion in PIH was so impressive, a fetoplacental origin of the increment in urinary epoxides seen in pregnant patients is possible. However In summary, we have developed a noninvasive, specific and sensitive method for measuring EETs and their corresponding vicinyl diols that establishes that P450-derived metabolites of arachidonic acid are formed in humans. Experiments in the dog suggest that the turnover of these compounds in plasma is rapid and that the contribution of circulating levels to urinary EETs is probably minimal under physiological conditions. We have also demonstrated that EET biosynthesis is increased in human pregnancy and that a further increment in formation of the 11,12-and 14,15-isomers occurs in patients with PIH. These observations and the in vitro properties of these compounds are consistent with the hypothesis that P450-derived metabolites of arachidonic acid are ofimportance in the physiological response to human pregnancy and the pathophysiology of PIH.
